Edition:
United States

ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

64.11USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$64.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
47,791
52-wk High
$65.75
52-wk Low
$42.26

Latest Key Developments (Source: Significant Developments)

ANI Pharmaceuticals Q3 gaap earnings per share $0.40
Thursday, 2 Nov 2017 08:30am EDT 

Nov 2 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance.Q3 adjusted Non-GAAP earnings per share $1.11.Q3 GAAP earnings per share $0.40.Q3 revenue $48.2 million versus I/B/E/S view $48.1 million.Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc sees ‍for full year 2017 net revenues $181 million to $183 million​.ANI Pharmaceuticals Inc sees ‍for full year 2017 adjusted Non-GAAP diluted earnings per share $3.83 to $4.00​.Q3 earnings per share view $0.99, revenue view $48.1 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $3.84, revenue view $182.1 million -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc - ‍ANI intends to request a meeting with fda in Q4 of 2017 to present its regulatory filing plan​.  Full Article

ANI Pharmaceuticals announces launch of Oxycodone Hydrochloride oral solution
Friday, 1 Sep 2017 08:30am EDT 

Sept 1 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals Inc announces approval and launch of Oxycodone Hydrochloride oral solution, 100 mg/5ml.ANI Pharmaceuticals Inc - ANI expects to begin shipping oxycodone hydrochloride oral solution, 100 mg/5ml to its customers immediately​.ANI Pharmaceuticals Inc - ‍received approval from U.S. FDA of its ANDA for Oxycodone Hydrochloride oral solution USP, 100 mg/5 ml.  Full Article

Ani pharmaceuticals reports Q2 adj. earnings of $0.98/shr
Thursday, 3 Aug 2017 08:30am EDT 

Aug 3 (Reuters) - Ani Pharmaceuticals Inc :Ani Pharmaceuticals reports record second quarter and year-to-date 2017 results and reaffirms guidance.Q2 adjusted non-GAAP earnings per share $0.98.Q2 GAAP earnings per share $0.23.Q2 revenue $44.8 million versus I/B/E/S view $43.2 million.Q2 earnings per share view $0.86 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $181 million to $190 million.Ani Pharmaceuticals Inc says reaffirms guidance for full year 2017​.FY 2017 revenue view $182.6 million -- Thomson Reuters I/B/E/S.  Full Article

ANI Pharmaceuticals announced launch of diphenoxylate hcl and atropine sulfate tablets
Tuesday, 20 Jun 2017 08:30am EDT 

June 20 (Reuters) - Ani Pharmaceuticals Inc :Ani Pharmaceuticals Inc - announced launch of diphenoxylate hcl and atropine sulfate tablets, 2.5mg/0.025mg.  Full Article

ANI Pharmaceuticals files for mixed shelf of up to $350.0 million
Monday, 12 Jun 2017 05:27pm EDT 

June 12 (Reuters) - ANI Pharmaceuticals Inc :Files for mixed shelf of up to $350.0 million .  Full Article

ANI Pharma announces launch of Pindolol tablets
Monday, 8 May 2017 09:15am EDT 

May 8 (Reuters) - Ani Pharmaceuticals Inc :Ani pharmaceuticals announces launch of pindolol tablets.Ani pharmaceuticals inc - launch of pindolol tablets, 5mg and 10mg, which is used in treatment of hypertension.  Full Article

Ani Pharmaceuticals reports Q1 GAAP earnings per share $0.10
Thursday, 4 May 2017 08:30am EDT 

May 4 (Reuters) - Ani Pharmaceuticals Inc ::Ani Pharmaceuticals reports first quarter results and year-to-date 2017 highlights and reaffirms guidance.Q1 adjusted non-gaap earnings per share $0.74.Q1 GAAP earnings per share $0.10.Q1 revenue rose 78 percent to $36.6 million.Sees FY 2017 revenue $181 million to $190 million.Ani Pharmaceuticals Inc - reaffirms guidance.Ani Pharmaceuticals Inc - ANI reaffirms guidance for full year 2017.FY2017 earnings per share view $3.87, revenue view $186.9 million -- Thomson Reuters I/B/E/S.  Full Article

ANI Pharmaceuticals reports Q4 loss per share $0.09
Thursday, 2 Mar 2017 08:30am EST 

ANI Pharmaceuticals Inc: Q4 adjusted non-gaap earnings per share $0.84 . Ani pharmaceuticals reports full year 2016 results and fourth quarter results and provides 2017 guidance . Q4 loss per share $0.09 . Q4 revenue rose 112 percent to $38.2 million . Ani pharmaceuticals inc sees 2017 adjusted non-gaap ebitda of $73.1 million to $77.2 million . Ani pharmaceuticals inc sees 2017 new adjusted non-gaap diluted earnings per share methodology yielding $3.58 to $3.94 per share . Ani pharmaceuticals inc says forecasting approximately $40 to $45 million in operating cash flow in 2017 . Ani pharmaceuticals inc says expect to invest upwards of $11 million in capital expenditures in 2017 .Fy2017 earnings per share view $4.44 -- Thomson Reuters I/B/E/S.  Full Article

Ani Pharmaceuticals pays about $20 mln in consideration for acquisition of Cranford assets
Friday, 24 Feb 2017 08:37am EST 

Ani Pharmaceuticals Inc : Ani Pharmaceuticals Inc - in consideration for acquisition of Cranford assets, company paid a purchase price of approximately $20 million - SEC filing .Ani Pharmaceuticals Inc- in consideration for acquisition of Holmdel assets, company paid a purchase price of approximately $31 million - sec filing.  Full Article

ANI Pharmaceuticals announces launch of authorized generic of lithobid extended release tablets
Wednesday, 21 Dec 2016 08:30am EST 

ANI Pharmaceuticals Inc - :ANI pharmaceuticals announces launch of authorized generic of lithobid extended release tablets.  Full Article

BRIEF-ANI Pharmaceuticals Q3 gaap earnings per share $0.40

* ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance